Introduction:
Boehringer Ingelheim has entered into a licensing and co-development deal with Kyowa Kirin to develop novel treatments for fibro-inflammatory diseases. Under the agreement, Boehringer Ingelheim will receive exclusive worldwide rights to develop the treatment, and Kyowa Kirin will receive up to €410 million in upfront and milestone payments, as well as royalties on sales. Fibro-inflammatory diseases are a significant cause of death worldwide, and there is a need for innovative treatments to address this global health issue.
- Boehringer Ingelheim has entered into a licensing and co-development deal with Kyowa Kirin to develop treatments for fibro-inflammatory diseases.
- The agreement grants Boehringer Ingelheim exclusive worldwide rights to develop the treatment.
- Kyowa Kirin will receive up to €410 million in upfront and milestone payments, as well as royalties on sales.
- Fibro-inflammatory diseases, such as systemic sclerosis, inflammatory bowel disease, and lung fibrosis, account for more than one third of deaths worldwide.
- This partnership represents a significant opportunity for Boehringer Ingelheim to expand its antifibrotics pipeline and address an unmet medical need.
Conclusion:
Boehringer Ingelheim’s licensing and co-development deal with Kyowa Kirin for fibro-inflammatory diseases presents an exciting opportunity to develop novel treatments for a significant global health issue. This partnership has the potential to make a meaningful impact on patient outcomes and further strengthen Boehringer Ingelheim’s antifibrotics pipeline.
